Quaglio AE, Magro DO, Imbrizi M, De Oliveira EC, Di Stasi LC, Sassaki LY. Creeping fat and gut microbiota in Crohn’s disease. World J Gastroenterol 2025; 31(1): 102042 [DOI: 10.3748/wjg.v31.i1.102042]
Corresponding Author of This Article
Ligia Y Sassaki, MD, PhD, Professor, Research Associate, Department of Internal Medicine, Medical School, São Paulo State University, Av. Prof. Montenegro-Distrito de, Botucatu-SP, Botucatu 18618-686, São Paulo, Brazil. ligia.sassaki@unesp.br
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Editorial
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 7, 2025; 31(1): 102042 Published online Jan 7, 2025. doi: 10.3748/wjg.v31.i1.102042
Creeping fat and gut microbiota in Crohn’s disease
Ana EV Quaglio, Daniéla O Magro, Marcello Imbrizi, Ellen CS De Oliveira, Luiz C Di Stasi, Ligia Y Sassaki
Ana EV Quaglio, Verum Ingredients, Botucatu Technology Park, Botucatu 18605-525, São Paulo, Brazil
Daniéla O Magro, Department of Surgery, Faculty of Medical Sciences, State University of Campinas, Campinas 13083-970, São Paulo, Brazil
Marcello Imbrizi, Department of Gastroenterology, Faculty of Medical Sciences, University of Campinas, Campinas 13083-970, São Paulo, Brazil
Ellen CS De Oliveira, Ligia Y Sassaki, Department of Internal Medicine, Medical School, São Paulo State University, Botucatu 18618-686, São Paulo, Brazil
Luiz C Di Stasi, Department of Biophysics and Pharmacology, Institute of Biosciences, São Paulo State University, Botucatu 18618-689, São Paulo, Brazil
Author contributions: Quaglio AEV, Magro DO, Imbrizi M, De Oliveira ECS, Di Stasi LC, and Sassaki LY contributed equally to the conception and design of the article, writing, and editing of the manuscript, and review of the literature; All the authors approved the final version of the article to be published.
Supported by the Postdoctoral Scholarship Grant, No. 5552/2024 PROPG/PROPE N°06/2024.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ligia Y Sassaki, MD, PhD, Professor, Research Associate, Department of Internal Medicine, Medical School, São Paulo State University, Av. Prof. Montenegro-Distrito de, Botucatu-SP, Botucatu 18618-686, São Paulo, Brazil. ligia.sassaki@unesp.br
Received: October 7, 2024 Revised: November 1, 2024 Accepted: November 13, 2024 Published online: January 7, 2025 Processing time: 62 Days and 14.6 Hours
Core Tip
Core Tip: Crohn’s disease is associated with creeping fat accumulation, influenced by factors such as gut microbiota. Dysbiosis, characterized by an increase in proteobacteria and species such as Clostridium innocuum, contributes to mesenteric fat accumulation and exacerbates inflammation. Modulating the microbiota through individualized interventions, such as environmental exposure modifications, fecal microbiota transplantation, and probiotics and prebiotics use, may be a potential strategy to reduce intestinal inflammation and mesenteric fat proliferation, improving therapeutic outcomes. However, further research is needed to elucidate the molecular mechanisms involved and develop biomarkers to identify patients who would benefit most from these approaches, considering their individual characteristics.
